Home World News Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve... World News Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 966 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... August 4, 2021 Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... June 17, 2020 ‘Jeopardy!’ Legend James Holzhauer Donates Portion Of Winnings To Cancer Walk... June 24, 2019 Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment September 24, 2021 Load more HOT NEWS How to Spot Suspicious Herb and Supplement Claims During Cancer ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... From smart knives to virtual reality tumours: five innovations in understanding... Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death...
